Back to top
more

TG Therapeutics, Inc. (TGTX)

(Real Time Quote from BATS)

$7.46 USD

7.46
3,465,896

-0.22 (-2.87%)

Updated Dec 6, 2019 01:26 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for TGTX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 1 - 20 ( 198 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 1

10/28/2019

Company Report

Pages: 8

Positive Data in Follicular Lymphoma Cohort of UNITY-NHL

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 2

10/24/2019

Daily Note

Pages: 4

Final Long-term Results for GENUINE Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 3

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for TGTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 4

09/12/2019

Daily Note

Pages: 3

Updated Phase 2 Extension Data for Ublituximab at ECTRIMS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 5

08/09/2019

Company Report

Pages: 6

2Q19 Results; Important Milestones in 4Q19 and Early 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 6

06/20/2019

Daily Note

Pages: 4

Positive Updated Data Presented at ICML in Lugano

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 7

06/11/2019

Daily Note

Pages: 3

Successful UNITY-NHL MZL Breakthrough Therapy Designation Meeting with FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 8

06/05/2019

Company Report

Pages: 8

Updated Umbralisib Data in MZL at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 9

05/13/2019

Company Report

Pages: 8

1Q19 Results; First FDA Submission Late 2019 or Early 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 10

04/12/2019

Daily Note

Pages: 3

Orphan Drug Designations Received for Three Marginal Zone Lymphoma Indications

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 11

04/02/2019

Company Report

Pages: 8

Umbralisib MZL Data at AACR Better Than Expected

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 12

03/08/2019

Company Report

Pages: 8

TG Therapeutics Reports 4Q18 Results; Model Update, Positive DSMB Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 13

02/28/2019

Daily Note

Pages: 4

UNITY Delivers: Positive Outcome Reported in Phase 2b UNITY-NHL Pivotal Trial in MZL Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 14

02/21/2019

Company Report

Pages: 9

Takeaways From Management Meetings With Investors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 15

01/22/2019

Daily Note

Pages: 3

TG Therapeutics Announces FDA Breakthrough Therapy Designation for Umbralisib in Treatment of MZL Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 16

12/18/2018

Daily Note

Pages: 3

TG Therapeutics and Dana-Farber Announce Phase 1/1B Umbralisib + Ibrutinib Combo Data Publication in Lancet Haematology

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 17

12/04/2018

Daily Note

Pages: 4

TG Therapeutics Presents Positive U2 Combination Data at ASH 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 18

11/13/2018

Daily Note

Pages: 3

TG Therapeutics Opens Phase 1 TG-1701 Enrollment in R/R B-Cell Malignancies; U2 Updates Expected at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 19

11/12/2018

Company Report

Pages: 8

TG Therapeutics 3Q18 Results; Awaiting Ublituximab and Umbralisib Data in 2019; PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 20

11/02/2018

Daily Note

Pages: 4

TG Therapeutics to Present Updated Umbralisib and Ublituximab Data at ASH 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party